Drug Profile
Research programme: USP15 inhibitors - Corbin Therapeutics/Proteorex Therapeutics
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Corbin Therapeutics; Proteorex Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action USP15 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Neurological-disorders in Canada (PO)
- 19 May 2017 Early research in Neurological disorders in Canada (PO)
- 19 May 2017 Corbin Therapeutics and Proteorex Therapeutics enter a research collaboration to develop USP15 protein inhibitors